Overview

Blinatumomab Bridging Therapy

Status:
Recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

The investigator is testing the ability of a biologically active therapy in blinatumomab, an anti-CD19/CD3 bispecific T-cell engager, to further reduce residual leukemia immediately prior to HCT to improve post-HCT outcomes.

Phase:

Phase 2

Details

Lead Sponsor:

Michael Burke

Collaborator:

Amgen

Treatments:

Blinatumomab